FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1984765273> ?p ?o ?g. }

• W1984765273 endingPage "1258" @default.
• W1984765273 startingPage "1249" @default.
• W1984765273 abstract "Background & Aims Outcomes in primary biliary cirrhosis (PBC) can be predicted by biochemical response to ursodeoxycholic acid (UDCA). Such stratification inadequately captures cirrhosis/portal hypertension, recognised factors associated with adverse events. Methods We evaluated a cohort of PBC patients (n = 386) attending the Liver Unit in Birmingham (derivation cohort), seeking to identify risk-variables associated with transplant-free survival independent of UDCA-response. A validation cohort was provided through well-characterised patients attending the Toronto Center for Liver Diseases (n = 479) and Jena University Hospital (n = 150). Results On multivariate analysis, factors at diagnosis associated with liver transplant (LT)/death were patient age (HR:1.06; p <0.001), elevated bilirubin (HR:1.27; p <0.001), early-onset cirrhosis (HR:2.40; p <0.001) and baseline AST/platelet ratio index (APRI) (HR:1.95; p <0.001). At 1-year, UDCA biochemical non-response predicted poorer transplant-free survival, and additional factors (multivariate) associated with adverse outcome were age (HR:1.02; p <0.05) and 1-year APRI (HR:1.15; p <0.001). Obtaining a cut-point from our derivation cohort, APRI >0.54 at baseline was predictive of LT/death (adjusted HR: 2.40; p <0.001), and retained statistical significance when applied at 1-year (APRI-r1, adjusted HR:2.75; p <0.001) despite controlling for UDCA-response. Across both cohorts, transplant-free survival was poorer for biochemical-responders with an APRI-r1 >0.54 vs. biochemical-responders with a lower APRI-r1 (p <0.01 and p <0.001, respectively); non-responders with high APRI-r1 had the poorest outcomes (p <0.001 and p <0.001). Conclusion In PBC, elevated APRI is associated with future risk of adverse events, independently and additively of UDCA-response. This cross-centre, robustly validated observation will contribute to ongoing efforts to refine existing risk-stratification tools, as well as direct focus for new therapies in patients with PBC. Outcomes in primary biliary cirrhosis (PBC) can be predicted by biochemical response to ursodeoxycholic acid (UDCA). Such stratification inadequately captures cirrhosis/portal hypertension, recognised factors associated with adverse events. We evaluated a cohort of PBC patients (n = 386) attending the Liver Unit in Birmingham (derivation cohort), seeking to identify risk-variables associated with transplant-free survival independent of UDCA-response. A validation cohort was provided through well-characterised patients attending the Toronto Center for Liver Diseases (n = 479) and Jena University Hospital (n = 150). On multivariate analysis, factors at diagnosis associated with liver transplant (LT)/death were patient age (HR:1.06; p <0.001), elevated bilirubin (HR:1.27; p <0.001), early-onset cirrhosis (HR:2.40; p <0.001) and baseline AST/platelet ratio index (APRI) (HR:1.95; p <0.001). At 1-year, UDCA biochemical non-response predicted poorer transplant-free survival, and additional factors (multivariate) associated with adverse outcome were age (HR:1.02; p <0.05) and 1-year APRI (HR:1.15; p <0.001). Obtaining a cut-point from our derivation cohort, APRI >0.54 at baseline was predictive of LT/death (adjusted HR: 2.40; p <0.001), and retained statistical significance when applied at 1-year (APRI-r1, adjusted HR:2.75; p <0.001) despite controlling for UDCA-response. Across both cohorts, transplant-free survival was poorer for biochemical-responders with an APRI-r1 >0.54 vs. biochemical-responders with a lower APRI-r1 (p <0.01 and p <0.001, respectively); non-responders with high APRI-r1 had the poorest outcomes (p <0.001 and p <0.001). In PBC, elevated APRI is associated with future risk of adverse events, independently and additively of UDCA-response. This cross-centre, robustly validated observation will contribute to ongoing efforts to refine existing risk-stratification tools, as well as direct focus for new therapies in patients with PBC." @default.
• W1984765273 created "2016-06-24" @default.
• W1984765273 creator A5004293364 @default.
• W1984765273 creator A5006656921 @default.
• W1984765273 creator A5008953573 @default.
• W1984765273 creator A5009370449 @default.
• W1984765273 creator A5014119297 @default.
• W1984765273 creator A5023060928 @default.
• W1984765273 creator A5026789922 @default.
• W1984765273 creator A5033458358 @default.
• W1984765273 creator A5037453305 @default.
• W1984765273 creator A5041454073 @default.
• W1984765273 creator A5042923287 @default.
• W1984765273 creator A5043626370 @default.
• W1984765273 creator A5065028057 @default.
• W1984765273 creator A5065843351 @default.
• W1984765273 creator A5078081528 @default.
• W1984765273 creator A5082997328 @default.
• W1984765273 date "2014-06-01" @default.
• W1984765273 modified "2023-10-01" @default.
• W1984765273 title "Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response" @default.
• W1984765273 cites W1969298821 @default.
• W1984765273 cites W1979310426 @default.
• W1984765273 cites W1994968614 @default.
• W1984765273 cites W1997865776 @default.
• W1984765273 cites W2005086332 @default.
• W1984765273 cites W2027496830 @default.
• W1984765273 cites W2027862649 @default.
• W1984765273 cites W2030290114 @default.
• W1984765273 cites W2032058959 @default.
• W1984765273 cites W2057537884 @default.
• W1984765273 cites W2058865320 @default.
• W1984765273 cites W2063027176 @default.
• W1984765273 cites W2063975050 @default.
• W1984765273 cites W2129639561 @default.
• W1984765273 cites W2141861294 @default.
• W1984765273 cites W2152758419 @default.
• W1984765273 cites W2153174384 @default.
• W1984765273 cites W2161458396 @default.
• W1984765273 cites W2786456523 @default.
• W1984765273 cites W4295008070 @default.
• W1984765273 doi "https://doi.org/10.1016/j.jhep.2014.01.029" @default.
• W1984765273 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24548531" @default.
• W1984765273 hasPublicationYear "2014" @default.
• W1984765273 type Work @default.
• W1984765273 sameAs 1984765273 @default.
• W1984765273 citedByCount "108" @default.
• W1984765273 countsByYear W19847652732014 @default.
• W1984765273 countsByYear W19847652732015 @default.
• W1984765273 countsByYear W19847652732016 @default.
• W1984765273 countsByYear W19847652732017 @default.
• W1984765273 countsByYear W19847652732018 @default.
• W1984765273 countsByYear W19847652732019 @default.
• W1984765273 countsByYear W19847652732020 @default.
• W1984765273 countsByYear W19847652732021 @default.
• W1984765273 countsByYear W19847652732022 @default.
• W1984765273 countsByYear W19847652732023 @default.
• W1984765273 crossrefType "journal-article" @default.
• W1984765273 hasAuthorship W1984765273A5004293364 @default.
• W1984765273 hasAuthorship W1984765273A5006656921 @default.
• W1984765273 hasAuthorship W1984765273A5008953573 @default.
• W1984765273 hasAuthorship W1984765273A5009370449 @default.
• W1984765273 hasAuthorship W1984765273A5014119297 @default.
• W1984765273 hasAuthorship W1984765273A5023060928 @default.
• W1984765273 hasAuthorship W1984765273A5026789922 @default.
• W1984765273 hasAuthorship W1984765273A5033458358 @default.
• W1984765273 hasAuthorship W1984765273A5037453305 @default.
• W1984765273 hasAuthorship W1984765273A5041454073 @default.
• W1984765273 hasAuthorship W1984765273A5042923287 @default.
• W1984765273 hasAuthorship W1984765273A5043626370 @default.
• W1984765273 hasAuthorship W1984765273A5065028057 @default.
• W1984765273 hasAuthorship W1984765273A5065843351 @default.
• W1984765273 hasAuthorship W1984765273A5078081528 @default.
• W1984765273 hasAuthorship W1984765273A5082997328 @default.
• W1984765273 hasConcept C126322002 @default.
• W1984765273 hasConcept C168563851 @default.
• W1984765273 hasConcept C197934379 @default.
• W1984765273 hasConcept C203092338 @default.
• W1984765273 hasConcept C2777214474 @default.
• W1984765273 hasConcept C2779609443 @default.
• W1984765273 hasConcept C2780366471 @default.
• W1984765273 hasConcept C2780965833 @default.
• W1984765273 hasConcept C2911091166 @default.
• W1984765273 hasConcept C50382708 @default.
• W1984765273 hasConcept C71924100 @default.
• W1984765273 hasConcept C72563966 @default.
• W1984765273 hasConcept C90924648 @default.
• W1984765273 hasConceptScore W1984765273C126322002 @default.
• W1984765273 hasConceptScore W1984765273C168563851 @default.
• W1984765273 hasConceptScore W1984765273C197934379 @default.
• W1984765273 hasConceptScore W1984765273C203092338 @default.
• W1984765273 hasConceptScore W1984765273C2777214474 @default.
• W1984765273 hasConceptScore W1984765273C2779609443 @default.
• W1984765273 hasConceptScore W1984765273C2780366471 @default.
• W1984765273 hasConceptScore W1984765273C2780965833 @default.
• W1984765273 hasConceptScore W1984765273C2911091166 @default.
• W1984765273 hasConceptScore W1984765273C50382708 @default.
• W1984765273 hasConceptScore W1984765273C71924100 @default.

• next